3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
5
Motor Activity
3
Sleep Wake Disorders
2
Overweight
2
Ovarian Neoplasms
2
Obesity
2
Colorectal Neoplasms
2
Colonic Neoplasms
2
Urinary Bladder Neoplasms
1
Thyroid Cancer, Papillary
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Neoplasms
1
Lung Neoplasms
1
Locally Advanced Head and Neck Squamous Cell Carcinoma
1
Kidney Neoplasms
1
Hematopoietic and Lymphatic System Neoplasm
1
Hematologic Neoplasms
1
Head and Neck Carcinoma
1
Fatigue
1
Endometrial Neoplasms
1
Depressive Disorder
1
Depression
1
Castration-Resistant Prostate Cancer (CRPC)
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Breast Carcinoma In Situ
1
Anxiety Disorders
1
Interventions
ruxolitinib
9
fludarabine phosphate
8
fludarabine
8
Whole-Body Irradiation
8
Specimen Handling
7
Cytarabine
7
Cyclophosphamide
7
Mycophenolic Acid
6
Tacrolimus
5
Injections
5
Busulfan
5
Biopsy
5
Azacitidine
5
Stem Cell Transplantation
4
Sirolimus
4
Peripheral Blood Stem Cell Transplantation
4
Melphalan
4
Granulocyte Colony-Stimulating Factor
4
CPX-351
4
venetoclax
3
luspatercept
3
decitabine and cedazuridine drug combination
3
Liposomes
3
Idarubicin
3
Daunorubicin
3
Cyclosporine
3
Blood Specimen Collection
3
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
3
selinexor
2
nilotinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Myeloproliferative Disorders
×
Counseling
×
90 days
×
Clear all
No trials found.